News

Back
December 16, 2019

Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma

Phase 1/2 Clinical Study Now Underway; Salarius Targeting Key Safety and Efficacy Data Milestones in 2020

Contact

Jeremy Feffer Managing Director jeremy@lifesciadvisors.com
Download PDF